APTX Aptinyx Inc.

-0.11  -3%
Previous Close 4.2
Open 4.18
Price To Book 0.84
Market Cap 137004137
Shares 33,497,344
Volume 234,857
Short Ratio
Av. Daily Volume 417,332

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due 1H 2019.
Parkinson’s Disease Cognitive Impairment (healthy volunteers)
Phase 2 full data due 1H 2019.
Phase 2 data released January 16, 2019 - primary endpoint not met.
Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Phase 2 trial initiation announced February 19, 2019 with data due 1H 2020.
Post-traumatic stress disorder (PTSD)

Latest News

  1. Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019
  2. Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference
  3. Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference
  4. Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder
  5. The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
  6. Biotech Play Aptinyx Tanks After Drug Trial Fails
  7. Why Ford Motor, Snap, and Aptinyx Slumped Today
  8. Here's Why Aptinyx Got Crushed Today
  9. Aptinyx stock falls 67% after phase 2 trial fails to meet primary endpoint
  10. Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
  11. Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference
  12. Should You Take Comfort From Insider Transactions At Aptinyx Inc. (NASDAQ:APTX)?
  13. Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting
  14. Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
  15. Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
  16. Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals — New Research Emphasizes Economic Growth
  17. Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights
  18. Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans
  19. Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy